Hailshadow
Disclosing new interim data from its Phase 1/2 AFFINITY DUCHENNE trial, Regenxbio (NASDAQ:RGNX) announced Thursday that its experimental gene therapy RGX-202 continued to benefit patients living with the muscle disorder Duchenne muscular dystrophy.
Citing data from the first five trial
